Sarcoidosis is not formally classified as an autoimmune disease, but it behaves like one in many ways. Despite decades of research, the exact cause remains unknown, and sarcoidosis sits in a gray zone between autoimmune and autoinflammatory conditions. It shares features with classic autoimmune diseases like lupus and rheumatoid arthritis, yet it lacks one of their hallmarks: specific, identifiable autoantibodies circulating in the blood.
Why the Classification Is Complicated
In a classic autoimmune disease, the immune system produces antibodies that mistakenly attack the body’s own tissues. Rheumatoid arthritis has rheumatoid factor. Lupus has anti-nuclear antibodies. These markers help doctors diagnose and monitor those conditions. Sarcoidosis has no equivalent. According to research from Johns Hopkins, known autoantibodies or useful serologic markers for diagnosing and monitoring sarcoidosis are lacking. If autoantibodies do show up in someone with sarcoidosis, it actually raises suspicion that a separate autoimmune disease may be mimicking or co-occurring with it.
That said, sarcoidosis clearly involves an immune system gone haywire. The disease produces clusters of immune cells called granulomas, most commonly in the lungs and lymph nodes. These granulomas form when the body’s defense system overreacts to something it perceives as a threat, then fails to shut that response down. The process involves many of the same immune pathways seen in autoimmune diseases, particularly an overactive T-cell response. Most researchers now describe sarcoidosis as “immune-mediated,” a broader term that captures its autoimmune-like behavior without requiring the specific antibody evidence that defines textbook autoimmune conditions.
How Granulomas Form
The leading theory is that sarcoidosis begins when an unknown trigger activates certain immune cells. Specialized cells called dendritic cells pick up the triggering substance and carry it to nearby lymph nodes, where they set off a cascade. Two types of helper T-cells (Th1 and Th17) multiply rapidly and flood the affected tissue. At the same time, immune cells in the lungs release a powerful inflammatory signal called TNF-alpha, which ramps up the local immune response even further.
Normally, this kind of response would clear an infection and then wind down. In sarcoidosis, the immune system never gets the “all clear.” The activated cells clump together into granulomas, which are tiny balls of inflamed tissue that can interfere with normal organ function. These granulomas are the defining feature of the disease and the reason it can affect so many different parts of the body.
Suspected Triggers
No single cause of sarcoidosis has been confirmed, but researchers have identified several exposures that appear to set the process in motion in people who are genetically susceptible. The leading candidates fall into two categories: infectious agents and environmental particles.
On the infectious side, mycobacteria (the family of bacteria that includes the one causing tuberculosis) have the most circumstantial evidence. A common skin bacterium called Propionibacterium acnes is the only microorganism that has actually been cultured from sarcoidosis lesions, making it another strong suspect. Neither has been proven to cause the disease directly.
Environmental exposures also play a clear role. Metal dusts, organic dusts, musty workplace environments, wood smoke, and fireplace use have all been linked to higher rates of sarcoidosis. Firefighters have notably elevated rates, and dust exposure from the World Trade Center disaster was associated with increased sarcoidosis diagnoses in the four years that followed. Silica dust exposure has been linked to both sarcoidosis and rheumatoid arthritis, another hint at shared immune mechanisms between the two.
Genetics and Susceptibility
Sarcoidosis runs in families, and specific genetic variations help explain why certain people develop it. Much of the genetic risk centers on HLA genes, which control how your immune system recognizes foreign substances. Certain versions of the HLA-DRB1 gene increase susceptibility. In African Americans, the DRB1*12:01 variant roughly doubles the risk, while the DRB1*11:01 variant raises it by about 70%. Other variants are protective, cutting the risk nearly in half.
Interestingly, the same genetic variants behave differently across ethnic groups and diseases. The DRB1*03:01 variant increases sarcoidosis susceptibility in Europeans but is also associated with a milder, self-resolving course. That same variant is a strong risk factor for lupus in white populations but carries no lupus risk in African Americans. These overlapping genetic connections further blur the boundary between sarcoidosis and recognized autoimmune diseases.
Who Gets Sarcoidosis
Sarcoidosis affects people of all backgrounds, but the burden falls unevenly. Black Americans are diagnosed at roughly twice the rate of white Americans, with an incidence of about 17.8 per 100,000 compared to 8.1. Hispanic and Asian populations have significantly lower rates (4.3 and 3.2 per 100,000, respectively). Black women bear the highest burden of any group, with a prevalence of 178.5 per 100,000 in managed healthcare data from 2009 to 2013. The peak age for diagnosis in Black women is 30 to 39, when the annual incidence reaches 107 per 100,000.
In Sweden, where the population is less racially diverse, the overall incidence is about 11.5 per 100,000. The disease is slightly more common in women than men across most populations studied.
Organs Affected Beyond the Lungs
The lungs are involved in roughly 90% of cases, but sarcoidosis can show up almost anywhere. When it spreads beyond the lungs, it most commonly affects the lymph nodes, liver, spleen, skin, and eyes. Among the more serious patterns is cardiac sarcoidosis, which one screening study found in 39% of ambulatory sarcoidosis patients. Many of those cases were clinically silent, with no obvious heart symptoms, though people with cardiac involvement were far more likely to report palpitations, fainting, or near-fainting episodes (46% vs. 5%).
Nervous system and eye involvement can also be devastating. These forms of sarcoidosis often require more aggressive treatment and monitoring from multiple specialists. Because the disease can affect so many organs simultaneously, the clinical picture varies enormously from person to person, which is one reason it takes an average of years to diagnose in many cases.
How Sarcoidosis Is Diagnosed
There is no single test for sarcoidosis. Diagnosis rests on three pillars: a clinical presentation that fits the disease, a tissue biopsy showing a specific type of inflammation called noncaseating granulomas, and the exclusion of other conditions that can cause similar granulomas (like tuberculosis, fungal infections, or beryllium exposure). The American Thoracic Society notes that because there are no objective measures to confirm each of these criteria has been fully met, “the diagnosis of sarcoidosis is never fully secure.”
This means diagnosis is partly a process of elimination. Doctors typically take a thorough history, perform imaging of the chest, and biopsy an affected lymph node or other tissue. If granulomas are found and no other explanation fits, sarcoidosis becomes the working diagnosis. Additional testing may be needed over time, especially if the disease doesn’t respond to treatment as expected.
Treatment and Outlook
Not everyone with sarcoidosis needs treatment. About 20% of patients experience spontaneous remission without any medication. For those who do need treatment, corticosteroids are the first choice. A typical starting dose is 20 to 40 mg of prednisone daily, tapered gradually over months. Once the dose reaches 10 mg per day, most doctors hold there for three to six months before reducing it further. The goal is to use the lowest effective dose, since long-term steroid use above 10 mg daily carries significant side effects including weight gain, bone thinning, and blood sugar problems.
For people who don’t respond to steroids, can’t tolerate them, or can’t get below 10 mg daily without flaring, methotrexate is the standard next step. It takes several weeks to reach full effect, so steroids are typically continued during the transition. In severe forms affecting the heart, brain, or eyes, some clinics start both medications together from the beginning. Even with this combination, roughly one-third of patients with treatment-resistant disease still don’t respond adequately.
Overall, about 58% of patients have a favorable prognosis, experiencing remission (with or without treatment), stable disease, or only minor recurrences. The remaining 42% face a more difficult course, with disease progression, chronic treatment dependence, or recurrences that require ongoing medication. Cardiac and neurological involvement tend to carry a more guarded outlook than disease limited to the lungs and lymph nodes.